SCOPUS 정보 검색 플랫폼

Volumn 94, Issue 4 SUPPL., 2002, Pages 1349-1357

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

(10) Wiseman, Gregory A a Leigh, Bryan b Erwin, William D c Lamonica, Dominick b,d Kornmehl, Ellen b,e Spies, Stewart M c Silverman, Daniel H S b,f Witzig, Thomas E a Sparks, Richard B b,g White, Christine A b

a MAYO CLINIC (United States)

b BIOGEN (United States)

c NORTHWESTERN UNIVERSITY (United States)

d ROSWELL PARK CANCER INSTITUTE (United States)

e HARVARD MEDICAL SCHOOL (United States)

f UCLA MEDICAL CENTER (United States)

g OAK RIDGE ASSOCIATED UNIVERSITIES (United States)

Author keywords

Dosimetry; IDEC Y2B8; NonHodgkin lymphoma; Radioimmunotherapy; Rituximab; Yttrium 90; Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB; INDIUM 111; MONOCLONAL ANTIBODY; PREDNISONE;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSIMETRY; HUMAN; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; B CELL LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; KIDNEY; LIVER; LUNG; MAJOR CLINICAL STUDY; MULTICENTER STUDY; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN;

EID: 0037083373 PISSN: 0008543X EISSN: None Source Type: Journal
DOI: 10.1002/cncr.10305 Document Type: Conference Paper

Times cited : (85)

References (19)

1
- 0033922969
- 90yttrium ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
- (2000) Eur J Nucl Med , vol.27 , pp. 766-777
- Wiseman, G.A.¹ White, C.A.² Stabin, M.³ Dunn, W.L.⁴ Erwin, W.⁵ Dahlbom, M.⁶

2
- 0034979977
- Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
- (2001) Crit Rev Oncol Hematol , vol.39 , pp. 181-194
- Wiseman, G.A.¹ White, C.A.² Sparks, R.B.³ Erwin, W.D.⁴ Podoloff, D.A.⁵ Lamonica, D.⁶

3
- 0033227592
- 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma
- (1999) Int J Oncol , vol.15 , pp. 1017-1025
- Chinn, P.C.¹ Leonard, J.E.² Rosenberg, J.³ Hanna, N.⁴ Anderson, D.R.⁵

4
- 0021272605
- Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
- (1984) Blood , vol.63 , pp. 1424-1433
- Anderson, K.C.¹ Bates, M.P.² Slaughenhoupt, B.L.³ Pinkus, G.S.⁴ Schlossman, S.F.⁵ Nadler, L.M.⁶

5
- 0028057250
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
- (1994) Blood , vol.83 , pp. 435-445
- Reff, M.E.¹ Carner, K.² Chambers, K.S.³ Chinn, P.C.⁴ Leonard, J.E.⁵ Raab, R.⁶

6
- 0004082410
- USA: U.S. Department of Energy
- (1981) Radioactive decay data tables: A handbook of decay data for application to radiation dosimetry and radiological assessments
- Kocher, D.C.¹

7
- 44949283598
- Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates
- (1991) Nucl Med Biol , vol.18 , pp. 369-381
- Gansow, O.¹

8
- 0032761164
- Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
- (1999) J Clin Oncol , vol.17 , pp. 3793-3803
- Witzig, T.E.¹ White, C.A.² Wiseman, G.A.³ Gordon, L.I.⁴ Emmanouilides, C.⁵ Raubitschek, A.⁶

9
- 0030002992
- MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine
- (1996) J Nucl Med , vol.37 , pp. 538-546
- Stabin, M.¹

10
- 0003923085
- New York, NY: Society of Nuclear Medicine
- (1991) MIRD primer for absorbed dose calculations (revised edition)
- Loevinger, R.¹ Budinger, T.² Watson, E.³

11
- 0027537029
- Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
- (1993) J Nucl Med , vol.34 , pp. 689-694
- Sgouros, G.¹

12
- 0014506735
- Erythrocyte volume, plasma volume, and lean body mass in adult men and women
- (1969) Blood , vol.33 , pp. 649-667
- Retzlaff, J.¹ Tauxe, W.² Kiely, J.³ Stroebel, C.⁴

13
- 0003258926
- Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL
- Abstract no. 3591
- (2000) Blood , vol.96
- Witzig, T.E.¹ White, C.A.² Gordon, L.I.³

14
- 0003262530
- Reduced dose Zevalin is safe and effective in patients with relapsed or refractory, low grade, follicular or CD20+ transformed B cell non-Hodgkin's lymphoma (L/F/T NHL) and mild thrombocytopenia
- Abstract no. 3149
- (2000) Blood , vol.96
- Witzig, T.E.¹ Gordon, L.I.² Wiseman, G.A.³

15
- 0003258929
- 90Y Zevalin radioimmunotherapy of rituximab-refractory follicular nonHodgkin's lymphoma
- Abstract no. 2183
- (2000) Blood , vol.96
- Witzig, T.E.¹ White, C.A.² Flinn, I.W.³

16
- 0033625513
- 111In-2ITBAD-Lym-1 in patients with non-Hodgkin's lymphoma
- (2000) J Nucl Med , vol.41 , pp. 952-958
- DeNardo, G.L.¹ O'Donnell, R.T.² Shen, S.³ Kroger, L.A.⁴ Yuan, A.⁵ Meares, C.F.⁶

17
- 0032697615
- 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
- (1999) Clin Cancer Res , vol.5
- Juweid, M.E.¹ Stadtmauer, E.² Hajjar, G.³ Sharkey, R.M.⁴ Suleiman, S.⁵ Luger, S.⁶

18
- 84866571598
- 131I anti-B-1 Mab lymphoma radioimmunotherapy: Is it feasible in a multicenter trial?
- Abstract no. 1546
- (1997) Immunol Biol Ther , vol.16
- Wahl, R.L.¹ Zasadny, K.S.² Gates, V.R.³

19
- 0041777466
- 131 tositumomab in non-Hodgkin's lymphoma
- Abstract no. 391
- (1999) Blood , vol.94
- Kostakoglu, L.¹ Leonard, J.P.² Coleman, M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.